Disability as an outcome in MS clinical trials.
BACKGROUND: Inferences about long-term effects of therapies in multiple sclerosis (MS) have been based on surrogate markers studied in short-term trials. Preventing progressive disability is the key therapeutic goal but there remains no validated definition for its measurement in a trial context. M...
Main Authors: | Ebers, G, Heigenhauser, L, Daumer, M, Lederer, C, Noseworthy, J |
---|---|
格式: | Journal article |
語言: | English |
出版: |
2008
|
相似書籍
-
Measuring disability progression in MS
由: Ebers, G, et al.
出版: (2005) -
Combined MRI lesions and relapses as a surrogate for disability in MS.
由: Ebers, G, et al.
出版: (2012) -
Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group.
由: Noseworthy, J, et al.
出版: (1990) -
Natural history of MS.
由: Ebers, G, et al.
出版: (2008) -
Surrogate endpoints for EDSS worsening in multiple sclerosis: a meta-analytic approach: measuring disability in relapsing-remitting MS.
由: Ebers, G, et al.
出版: (2011)